Muscle Relaxant Tablet Franchise in Ahmedabad

Epihype 150 Tablet Supplier in Mumbai

Musculoskeletal Pain Relief Tablet Distributor in Delhi

Eperisone Tablet Manufacturer in Bangalore

Orthopedic Therapy Tablet Stockist in Hyderabad
Muscle Relaxant Tablet Exporter in Chandigarh

Home/Products /eperisone-150mg-tablet

Epihype 150 Tablet

Composition : Eperisone (150mg) Tablet

Dosage Form : Tablet

Packaging Type : Alu Alu

Packaging : 10*10

Price : ₹0/-

Epihype 150 Tablet contains Eperisone 150 mg, a centrally acting skeletal muscle relaxant that works by reducing excessive muscle contraction and improving blood circulation in affected muscles. It effectively alleviates muscle stiffness, pain, and restricted movement associated with musculoskeletal disorders.

Clinically, Eperisone is indicated for acute and chronic muscle spasm, cervical and lumbar spondylosis, post-traumatic muscle stiffness, and orthopedic or neurological spastic conditions. The higher 150 mg strength is particularly useful in patients requiring enhanced muscle relaxation and sustained symptom control.

The tablet formulation ensures precise dosing, reliable absorption, and consistent therapeutic action, making it suitable for use in orthopedic clinics, physiotherapy centers, neurology practices, and hospital outpatient departments. Oral administration supports ease of use and improved patient compliance.

Epihype 150 Tablet helps in reducing muscle rigidity, improving range of motion, and enhancing overall functional recovery. Its favorable tolerability profile makes it a preferred muscle relaxant therapy option when prescribed under appropriate medical supervision.

Read More

About the Product

Epihype 150 Tablet contains Eperisone 150 mg, a centrally acting skeletal muscle relaxant that works by reducing excessive muscle contraction and improving blood circulation in affected muscles. It effectively alleviates muscle stiffness, pain, and restricted movement associated with musculoskeletal disorders.

Clinically, Eperisone is indicated for acute and chronic muscle spasm, cervical and lumbar spondylosis, post-traumatic muscle stiffness, and orthopedic or neurological spastic conditions. The higher 150 mg strength is particularly useful in patients requiring enhanced muscle relaxation and sustained symptom control.

The tablet formulation ensures precise dosing, reliable absorption, and consistent therapeutic action, making it suitable for use in orthopedic clinics, physiotherapy centers, neurology practices, and hospital outpatient departments. Oral administration supports ease of use and improved patient compliance.

Epihype 150 Tablet helps in reducing muscle rigidity, improving range of motion, and enhancing overall functional recovery. Its favorable tolerability profile makes it a preferred muscle relaxant therapy option when prescribed under appropriate medical supervision.

Common side effects may include dizziness, drowsiness, nausea, weakness, or gastrointestinal discomfort. Rarely, hypotension, skin rash, or liver enzyme elevation may occur.

Epihype 150 Tablet is indicated for the management of muscle spasticity associated with cervical spondylosis, lumbar spondylosis, periarthritis of the shoulder, low back pain, and post-traumatic muscle spasms, as prescribed by a physician.

Epihype 150 Tablet should be used under medical supervision. Caution is advised in patients with liver impairment or those operating heavy machinery. Do not exceed the prescribed dose. Discontinue use and consult a doctor if severe allergic reactions or persistent side effects occur.

Store in a cool, dry place below 25°C. Protect from moisture and direct sunlight. Keep out of reach of children.

Get in Touch

Regulatory Compliance & Professional Verification

This catalog is a digital representation of the Cafoli Lifecare portfolio and is intended for use by authorized pharmaceutical distributors and PCD franchise partners.

  • No Consumer Sale: We do not entertain retail inquiries or direct sales to patients.
  • Information Accuracy: While we strive for accuracy, product availability, packaging, and regulatory status may change based on CDSCO guidelines and state-specific drug laws.
  • Medical Advice: Patients are strictly advised not to self-medicate or use this information for treatment. Always consult a qualified medical practitioner.
  • Licensing: All business associations are subject to the submission of valid GST and Drug License (DL) documentation.

Strategic Advisory

Ms. Shiwani Dhiman

VP-Strategic Outreach & Engagement

Ms. Shiwani specializes in market outreach and strategic partnership orchestration for entrepreneurs building scalable PCD Pharma Franchise models.

View Professional Profile

Start Your Journey

Partner With Cafoli

Ready to Dominate your territory with a Monopoly-Based PCD Franchise? Join our rapidly growing network of successful franchise partners and turn your ambitions into reality. Limited Territories Available — Don’t Miss Out!

Quick Navigation